SCHEDULE 13G/A: Rosalind Advisors and Affiliates Maintain Significant Stake in Myomo, Inc. Amidst Blocker Provisions

Rosalind Advisors, Inc. and its affiliates have filed an amended Schedule 13G/A, disclosing a continued beneficial ownership of Myomo, Inc. common stock, including pre-funded warrants subject to a 9.99% ownership blocker.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported a potential beneficial ownership of 7,574,330 shares of Myomo, Inc. common stock as of December 31, 2024.
• This potential aggregate amount, which includes 2,998,945 shares of common stock and 4,575,385 shares issuable upon the exercise of pre-funded warrants, represents 9.9% of Myomo, Inc.'s common stock outstanding, based on 33,244,155 shares outstanding as of December 5, 2024.
• However, a critical "blocker provision" on the pre-funded warrants prevents the holder from exercising them to the extent that it would result in beneficial ownership exceeding 9.99% of the Common Stock.
• Consequently, as of the reporting date, the Reporting Persons were unable to exercise any of the 4,575,385 pre-funded warrants due to these blocker provisions.
• The actual number of shares beneficially owned by Rosalind Master Fund L.P., after giving effect to these blockers, is 2,998,945 shares of common stock, representing approximately 9.02% of the outstanding common stock.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Myomo, Inc.

Sentiment

Score: 6

Explanation: The filing is neutral in tone, primarily a factual disclosure of beneficial ownership. The continued significant stake by a major investor is mildly positive, but the inability to exercise a large portion of warrants due to blockers introduces a slight negative nuance regarding the investor's immediate flexibility.

Positives

• Continued significant investment by Rosalind Advisors and affiliates, indicating ongoing confidence in Myomo, Inc.
• The investment is stated to be for ordinary course of business, not for control, suggesting a passive, supportive shareholder.

Negatives

• The existence of blocker provisions on pre-funded warrants limits the immediate conversion of these securities into common stock, potentially restricting the investor's full participation or influence.
• The inability to exercise warrants due to the blocker provisions means a substantial portion of their potential ownership (4,575,385 shares) is not currently realized as common stock.

Risks

• Blocker Provisions: The pre-funded warrants held by Rosalind Master Fund L.P. contain a blocker provision that prevents exercise if it would result in beneficial ownership exceeding 9.99% of Myomo, Inc.'s common stock. This limits the investor's ability to fully convert their warrants into common shares.
• Dilution Risk (Future): While currently blocked, the potential future exercise of 4,575,385 pre-funded warrants, if the blocker is removed or the outstanding share count increases significantly, could lead to dilution for existing shareholders.

Future Outlook

The document does not provide forward-looking statements or guidance regarding Myomo, Inc.'s future performance or strategic direction, as it is a beneficial ownership disclosure.

Industry Context

This filing indicates a significant, passive investment by an institutional investor in Myomo, Inc., a company likely operating in the medical device or rehabilitation technology sector. Such filings are common for institutional investors accumulating stakes in public companies, reflecting their investment strategy rather than broader industry trends.

Comparison to Industry Standards

• This Schedule 13G/A filing is a standard regulatory disclosure for investors acquiring more than 5% of a company's stock with a passive intent.
• The beneficial ownership percentage of 9.9% (potential) and 9.02% (actual) represents a substantial stake, nearing the 10% threshold that often triggers additional regulatory scrutiny or changes in filing requirements (e.g., Schedule 13D).
• The use of blocker provisions in pre-funded warrants is a common mechanism employed by institutional investors to manage their ownership percentage below certain thresholds (e.g., 10%) to avoid becoming an 'insider' or triggering other regulatory obligations, while still maintaining a significant economic interest.
• No specific comparable companies, projects, or results are mentioned in the filing.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake. The blocker provision means less immediate dilution from warrant exercise than the total potential shares might suggest.
• Company Management: Awareness of a large, passive shareholder.

Next Steps

• The document does not mention any specific future actions, events, or milestones for Myomo, Inc. or the reporting persons beyond the ongoing beneficial ownership.

Key Dates

Recommendation

Keywords

Myomo Inc., MYO, Schedule 13G/A, Beneficial Ownership, Rosalind Advisors, Rosalind Master Fund, Pre-funded Warrants, Blocker Provision, Institutional Investor, SEC Filing, Common Stock